Kirkland & Ellis LLP-advised pharmaceutical giant Eli Lilly & Co. on Monday announced plans to acquire clinical-stage biotechnology company Kelonia Therapeutics, led by Goodwin Procter LLP, in a deal worth up to $7 billion.
Continue Reading
Sign up for FREE to read the full article and access 129K+ alternative investment headlines.